Northstrive Biosciences Announces Positive FDA Response Supporting A Submission Of IND For A Phase 2 Clinical Trial For EL-22 In Combination With GLP-1 Receptor Agonist For Obesity Treatment
April 24 (Reuters) - PMGC Holdings Inc ELAB.O:
NORTHSTRIVE BIOSCIENCES ANNOUNCES POSITIVE FDA RESPONSE SUPPORTING A SUBMISSION OF IND FOR A PHASE 2 CLINICAL TRIAL FOR EL-22 IN COMBINATION WITH GLP-1 RECEPTOR AGONIST FOR OBESITY TREATMENT
PMGC HOLDINGS INC - NORTHSTRIVE TO FILE IND APPLICATION IN 2025
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.